In8bio Inc (INAB)

In8bio Inc (INAB) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $13.8M; returns 1 day +6.5%, 1 week -5.4%, 1 year -50.0%.

In8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for treating cancer and autoimmune diseases. Their proprietary DeltEx platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies designed to identify and eradicate tumor cells.

Groups INAB belongs to

• Biotechnology
• Clinical Stage Biotech
• Healthcare
• Biopharmaceutical
• Oncology
• Clinical Stage
• Immunotherapy
• Cancer Therapeutics
• Life Sciences
• Autologous Cell Therapy

INAB financial model: income statement, cash flow and balance sheet